Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).
作者信息
Sharma Ashish, Kaiser Peter K, Tadayoni Ramin, Holz Frank G, Nicholson Luke, Vazquez-Alfageme Clara, Sivaprasad Sobha, Wakabayashi Taku, Woo Se Joon, Sarraf David, Kumar Nilesh, Parachuri Nikulaa, Regillo Carl D, Rezaei Kourous A, Khanani Arshad M, Bandello Francesco, Shanamugam Mahesh, Verma Lalit, Dogra Mangat Ram, Ns Muralidhar, Agarwal Manisha, Loewenstein Anat, Kuppermann Baruch D
机构信息
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
出版信息
Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26.
Abstract
摘要
相似文献
1
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).国际视网膜生物类似药研究小组（国际生物类似药小组）与印度玻璃体视网膜协会（VRSI）合作开展的《2023年印度视网膜疾病抗VEGF生物类似药调查》（Bio-INDAS）
Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26.
2
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
3
Preferred practice patterns of endophthalmitis management and prevention: A survey among the members of Vitreoretinal Society of India - Study by the VRSI study group.眼内炎管理与预防的最佳实践模式：印度玻璃体视网膜学会成员的一项调查——VRSI研究小组的研究
Indian J Ophthalmol. 2025 Jun 1;73(6):881-885. doi: 10.4103/IJO.IJO_2757_24. Epub 2025 May 28.
4
A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?美国生物类似药批准的系统评价：FDA 需要什么证据，制造商如何回应？
J Manag Care Spec Pharm. 2017 Dec;23(12):1234-1244. doi: 10.18553/jmcp.2017.23.12.1234.
5
Biosimilar monoclonal antibodies for cancer treatment in adults.用于成人癌症治疗的生物类似单克隆抗体。
Cochrane Database Syst Rev. 2024 Nov 28;11(11):CD013539. doi: 10.1002/14651858.CD013539.pub2.
6
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.肿瘤生物类似药的比较安全性概况：系统评价与网状Meta分析
BioDrugs. 2023 Mar;37(2):205-218. doi: 10.1007/s40259-023-00576-8. Epub 2023 Feb 2.
7
Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema.贝伐珠单抗生物类似药在初治糖尿病性黄斑水肿患者中的疗效、安全性和成本效益。
Indian J Pharmacol. 2024 Jul 1;56(4):248-252. doi: 10.4103/ijp.ijp_58_24. Epub 2024 Sep 10.
8
Vitreoretinal Society of India practice pattern survey 2020: Medical retina.2020年印度玻璃体视网膜学会实践模式调查：医学视网膜
Indian J Ophthalmol. 2021 Jun;69(6):1430-1439. doi: 10.4103/ijo.IJO_2573_20.
9
10
Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.抗肿瘤坏死因子-α 生物类似药在风湿性疾病中的疗效、安全性和药代动力学：系统评价和荟萃分析。
J Autoimmun. 2017 May;79:4-16. doi: 10.1016/j.jaut.2017.02.003. Epub 2017 Feb 13.
引用本文的文献
1
Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV.雷珠单抗生物类似药治疗继发于湿性年龄相关性黄斑变性（nAMD）和息肉状脉络膜血管病变（PCV）的黄斑新生血管后，基于频域光学相干断层扫描（En-face OCT）的最小强度液体变化的定量评估
Clin Ophthalmol. 2025 Jul 29;19:2505-2512. doi: 10.2147/OPTH.S542496. eCollection 2025.
2
Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).阿柏西普2毫克生物类似药（Tyalia）——来自伊朗的真实世界经验（ATRIA研究）
Eye (Lond). 2025 May 3. doi: 10.1038/s41433-025-03813-2.
3
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.生物类似药雷珠单抗（Ranieyes）在现实世界中的安全性和有效性：BRESER研究
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
本文引用的文献
1
Approved biosimilar ranibizumab-a global update.已批准的雷珠单抗生物类似药——全球最新情况
Eye (Lond). 2023 Feb;37(2):200-202. doi: 10.1038/s41433-022-02246-5. Epub 2022 Sep 16.
2
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
3
Biosimilars for Retinal Diseases: An Update.视网膜疾病的生物类似药：最新进展
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
4
Ophthalmic biosimilars: Lessons from India.眼科生物类似药：来自印度的经验教训。
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
Zotero 插件